GLTO

#3569
Galecto, Inc. Common Stock
29.58
-6.81%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
29.58
29.58
Jahresspanne
2.01
38.33
Tagesänderung
-6.81%
Monatliche Änderung
+19.71%
6 month change
+782.99%
Jahresänderung
+587.91%
Vorheriger Schlusskurs
31.74
Open
29.58
Bid
Ask
Low
29.58
High
29.58
Volumen
23
Open full chart

Financials

Overview Finanzbericht Statistics Dividends
Quarterly Annual
  • Market Capitalization 39.25 M
  • Employee 5
  • Founded 2011
  • CEO Hans T. Schambye
  • Website www.galecto.com
  • Headquarter Delaware, United States
  • FIGI BBG00XMLGWC5
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-0.31
Price to sales ratio
20.46
Dividends per share
—
Dividend yield %
—

Galecto Inc

Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark. The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need.

Nachrichten